| Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial DM Gershenson, A Miller, WE Brady, J Paul, K Carty, W Rodgers, D Millan, ... The Lancet 399 (10324), 541-553, 2022 | 127 | 2022 |
| Clear cell carcinoma of the ovary: a clinical and molecular perspective Y Iida, A Okamoto, R Hollis, C Gourley, CS Herrington International Journal of Gynecologic Cancer, ijgc-2020-001656, 2020 | 109 | 2020 |
| Genetic and molecular changes in ovarian cancer RL Hollis, C Gourley Cancer biology & medicine 13 (2), 236, 2016 | 100 | 2016 |
| Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome RL Hollis, JP Thomson, B Stanley, AM Meynert, T Rye, C Bartos, Y Iida, ... Nature Communications 11, 4995, 2020 | 85 | 2020 |
| Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer SP Langdon, CS Herrington, RL Hollis, C Gourley Cancers 12 (6), 1647, 2020 | 77 | 2020 |
| Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer RL Hollis, M Churchman, C Gourley OncoTargets and therapy 10, 2539, 2017 | 63 | 2017 |
| Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data A Irodi, T Rye, K Herbert, M Churchman, C Bartos, M Mackean, F Nussey, ... BJOG: An International Journal of Obstetrics & Gynaecology, 2020 | 38 | 2020 |
| Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma A Ewing, A Meynert, M Churchman, G Grimes, RL Hollis, CS Herrington, ... Clinical Cancer Research, 2021 | 35 | 2021 |
| High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum RL Hollis, M Churchman, CO Michie, T Rye, L Knight, A McCavigan, ... Cancer, 2019 | 33 | 2019 |
| Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors B Stanley, RL Hollis, H Nunes, JD Towler, X Yan, T Rye, C Dawson, ... Gynecologic oncology 152 (2), 278-285, 2019 | 31 | 2019 |
| Molecular characteristics and clinical behaviour of epithelial ovarian cancers RL Hollis Cancer Letters, 216057, 2023 | 27 | 2023 |
| Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells MK Gomez, G Illuzzi, C Colomer, M Churchman, RL Hollis, MJ O’Connor, ... Cancers 12 (6), 1503, 2020 | 25 | 2020 |
| Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse RL Hollis, J Carmichael, AM Meynert, M Churchman, A Hallas-Potts, ... American Journal of Obstetrics & Gynecology, 2019 | 25 | 2019 |
| Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma RL Hollis, B Stanley, Y Iida, J Thomson, M Churchman, T Rye, ... Gynecologic oncology, 2019 | 23 | 2019 |
| Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high grade serous carcinoma RL Hollis, I Croy, M Churchman, C Bartos, T Rye, C Gourley, ... British Journal of Cancer 127 (6), 1034-1042, 2022 | 22 | 2022 |
| Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification RL Hollis, AM Meynert, CO Michie, T Rye, M Churchman, A Hallas-Potts, ... Clinical Cancer Research 28 (16), 3546-3556, 2022 | 17 | 2022 |
| Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations RL Hollis, AM Meynert, M Churchman, T Rye, M Mackean, F Nussey, ... BMC cancer 18 (1), 16, 2018 | 17 | 2018 |
| Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification RL Hollis, B Stanley, JP Thomson, M Churchman, I Croy, T Rye, C Bartos, ... npj Precision Oncology 5 (1), 1-9, 2021 | 14 | 2021 |
| Infection‐driven activation of transglutaminase 2 boosts glucose uptake and hexosamine biosynthesis in epithelial cells B Maffei, M Laverrière, Y Wu, S Triboulet, S Perrinet, M Duchateau, ... The EMBO Journal, 2020 | 12 | 2020 |
| Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma RL Hollis, LJ Stillie, S Hopkins, C Bartos, M Churchman, T Rye, F Nussey, ... Cancers 13 (22), 5839, 2021 | 9 | 2021 |
